The future of obesity treatment lies in combining powerful drug therapies with clinician-led lifestyle interventions.
In this episode, Rob MacNaughton, CEO of Calibrate, discusses the company’s pioneering approach to weight management. He shares how Calibrate blends anti-obesity medications with clinician-led lifestyle interventions to ensure sustainable weight loss outcomes. This model not only helps individuals maintain weight loss but also drives better healthcare outcomes while reducing costs. Rob highlights Calibrate’s commitment to clinical integrity and ongoing research into tapering medication and long-term success, providing valuable insights into the future of obesity treatment.
Tune in and learn how combining medication with lifestyle changes is transforming obesity treatment and delivering lasting health benefits!
About Rob MacNaughton:
Rob MacNaughton is the CEO of Calibrate and a leader in weight and obesity management. With a strong background in operations, strategic planning, and product development, Rob has focused on innovative solutions to manage obesity using a combination of anti-obesity medications and lifestyle interventions.
Things You’ll Learn:
Calibrate combines anti-obesity medications and lifestyle interventions to achieve sustainable weight loss.
Real-world results demonstrate how Calibrate enables individuals to maintain weight loss even after stopping medication.
Clinical integrity and data-driven solutions are essential in addressing obesity effectively.
Self-insured employers are increasingly promoting sustainable health outcomes through corporate wellness programs.
Resources:
